{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:35:26Z","timestamp":1794105326801,"version":"4.8.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejmech.2021.113842","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T01:49:34Z","timestamp":1631324974000},"page":"113842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research"],"prefix":"10.1016","volume":"226","author":[{"given":"Xianbo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiali","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaodan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113842_bib1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113842_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2021.113842_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173208","article-title":"Neuroprotection: a versatile approach to combat glaucoma","volume":"881","author":"Naik","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113842_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41434-019-0105-4","article-title":"Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristics","volume":"27","author":"Rodriguez-Estevez","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/APO.0000000000000264","article-title":"Global blindness: the progress we are making and still need to make","volume":"8","author":"Hr","year":"2019","journal-title":"Asia Pac J Ophthalmol(Phila)."},{"key":"10.1016\/j.ejmech.2021.113842_bib6","first-page":"1897","article-title":"In-Silico analysis to identify the potent inhibitor of Rho GTPase activating protein for the usage of the Glaucoma","volume":"37","author":"Thiruchelvi","year":"2021","journal-title":"Mater. Today: Proc."},{"key":"10.1016\/j.ejmech.2021.113842_bib7","doi-asserted-by":"crossref","first-page":"105648","DOI":"10.1016\/j.ejps.2020.105648","article-title":"Glaucoma: management and future perspectives for nanotechnology-based treatment modalities","volume":"158","author":"El Hoffy","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib8","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1167\/iovs.06-0830","article-title":"Aqueous humor outflow: what do we know? Where will it lead us?","volume":"47","author":"Fautsch Mp","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib9","doi-asserted-by":"crossref","first-page":"C1057","DOI":"10.1152\/ajpcell.00481.2007","article-title":"Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork","volume":"295","author":"Zhang M","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2021.113842_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2017.0041","article-title":"Targets of neuroprotection in glaucoma","volume":"34","author":"He","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib11","series-title":"Novel Therapeutic Targets for Glaucoma: Disease Modification Treatment, Neuroprotection, and Neuroregeneration, Medical Treatment of Glaucoma","first-page":"147","author":"Kwong","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113842_bib12","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1517\/14656560903300103","article-title":"Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics","volume":"10","author":"Costagliola","year":"2009","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113842_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma. 4th edition - chapter 3: treatment principles and options supported by the EGS foundation. Part 1: foreword; intro-duction; glossary; Chapter 3 treatment principles and options","volume":"101","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib14","article-title":"Association between topical beta-blockers and risks of cardiovascular and respiratory disease in patients with glaucoma: a retrospective cohort study","volume":"10","author":"Chen","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejmech.2021.113842_bib15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","article-title":"The mechanism of timolol in lowering intraocular pressure","volume":"96","author":"Coakes","year":"1978","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exer.2011.04.002","article-title":"Update on the role of alpha-agonists in glaucoma management","volume":"93","author":"Arthur S","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib17","first-page":"1641","article-title":"Japan Glaucoma Society, the prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study","volume":"111","author":"Iwase A","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2021.113842_bib18","first-page":"1661","article-title":"Tajimi Study Group. Japan Glaucoma Society, the Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population","volume":"112","author":"Yamamoto T","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2021.113842_bib19","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archopht.1984.01040031262032","article-title":"Alteration of acetylcholine synthesis by pilocarpine in\u00a0vivo and in\u00a0vitro studies","volume":"102","author":"Mindel","year":"1984","journal-title":"Arch ophthamol"},{"key":"10.1016\/j.ejmech.2021.113842_bib20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1517\/14656560903300129","article-title":"Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides","volume":"10","author":"Costagliola","year":"2009","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113842_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113842_bib22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/13543776.2019.1679117","article-title":"Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019","volume":"29","author":"Supuran","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113842_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13543784.2018.1526279","article-title":"Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma","volume":"27","author":"Matsou","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.113842_bib24","first-page":"1475","article-title":"Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues","volume":"43","author":"Schl\u00f6tzer Schrehardt U","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib25","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1167\/iovs.10-6510","article-title":"The role of the prostaglandin EP4 receptor in the regulation of human outflow facility","volume":"52","author":"Millard","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib26","first-page":"424","article-title":"Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization","volume":"42","author":"Mukhopadhyay","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib27","first-page":"614","article-title":"Latanoprost and periocular skin color changes","volume":"119","author":"Wand","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib28","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1167\/iovs.05-1627","article-title":"The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey","volume":"47","author":"Nilsson","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jop.2018.0095","article-title":"Dose\u2013response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure","volume":"35","author":"Lee","year":"2019","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib30","first-page":"21","article-title":"Sustained-release travoprost: data at 12 months. News in review: commentary and perspective","author":"October","year":"2018","journal-title":"Eyenet Mag."},{"key":"10.1016\/j.ejmech.2021.113842_bib31","first-page":"31","article-title":"Core-shell lipid-polymer nanoparticles as a promising ocular drug delivery system to treat glaucoma","author":"Zhou","year":"2019","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113842_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/pharmaceutics4010197","article-title":"Ocular drug delivery for glaucoma management","volume":"4","author":"Gooch","year":"2012","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ejmech.2021.113842_bib33","article-title":"DE-117, a selective EP2 agonist, lowered intraocular pressure in animal models","volume":"56","author":"Kirihara T","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/jop.2019.0044","article-title":"Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, nonprostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and caucasian volunteers (phase I study)","volume":"35","author":"Makoto Aihara","year":"2019","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib35","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","article-title":"Identification of a selective, non-prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl","volume":"61","author":"Iwamura","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113842_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib37","first-page":"5708","article-title":"Safety and efficacy of DE-117, a selective EP2 agonist in a phase 2a study","volume":"56","author":"Ihekoromadu N","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J.\u00a0Glaucoma"},{"key":"10.1016\/j.ejmech.2021.113842_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040301","article-title":"Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study","volume":"11","author":"Nakakura","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejmech.2021.113842_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1268","article-title":"Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype","volume":"7","author":"Qu","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.ejmech.2021.113842_bib41","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1021\/jm401431x","article-title":"Prostanoid receptor EP2 as a therapeutic target","volume":"57","author":"Ganesh","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113842_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A\u00a0phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1523\/JNEUROSCI.4485-03.2004","article-title":"Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia","volume":"24","author":"McCullough","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.113842_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2040-7378-2-12","article-title":"The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke","volume":"2","author":"Ahmad","year":"2010","journal-title":"Exp. Transl. Stroke Med."},{"key":"10.1016\/j.ejmech.2021.113842_bib45","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.14-16181","article-title":"IOP-lowering effect of ONO-9054, A novel dual agonist of prostanoid EP3 and FP receptors, in monkeys","volume":"56","author":"Yamane","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib46","first-page":"70","article-title":"Discovery of a novel glaucoma oriented EP3\/FP dual agonist ONO-9054","volume":"27","author":"God toru","year":"2017","journal-title":"Medchem News"},{"key":"10.1016\/j.ejmech.2021.113842_bib47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2016-309023","article-title":"Ocular hypotensive effect of the novel EP3\/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study","volume":"101","author":"Miller Ellis","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib48","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1097\/IJG.0000000000000449","article-title":"Ocular hypotensive effect of ONO-9054, an EP3\/FP receptor agonist: results of a randomized, placebo-controlled, dose escalation study","volume":"25","author":"Harris","year":"2016","journal-title":"J.\u00a0Glaucoma"},{"key":"10.1016\/j.ejmech.2021.113842_bib49","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1167\/iovs.15-18166","article-title":"A\u00a0novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and accepted manuscript pharmacodynamics of ONO-9054 in healthy volunteers","volume":"56","author":"Suto F","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bjophthalmol-2015-307000","article-title":"EP3\/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study","volume":"100","author":"Berlin","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib51","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1060028014548569","article-title":"Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension","volume":"48","author":"Lin","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113842_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/ICU.0b013e32832b7578","article-title":"Dry eye in 2008","volume":"20","author":"Abelson Mb","year":"2009","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/ICO.0b013e3181c11e45","article-title":"Diurnal variation of visual function and the signs and symptoms of dry eye","volume":"29","author":"Walker","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.ejmech.2021.113842_bib54","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.exer.2009.05.002","article-title":"Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models","volume":"89","author":"Prasanna","year":"2009","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.109.157800","volume":"331","author":"Luu","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib56","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1021\/jo301277n","article-title":"SmI2-mediated intermolecular coupling of gamma-lactam N-alpha-radicals with activated alkenes: asymmetric synthesis of 11-hydroxylated analogues of the lead compounds CP-734432 and PF-04475270","volume":"78","author":"Hu","year":"2013","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113842_bib57","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Jd","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113842_bib58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cclet.2015.03.002","article-title":"Improved thromboresistance and analytical performance of intravascular amperometric glucose sensors using optimized nitric oxide release coatings","volume":"26","author":"Wolf","year":"2015","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113842_bib59","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.cclet.2016.01.043","article-title":"Synthesis and pharmacological properties of naturally occurring prenylated and pyranochalcones as potent anti-inflammatory agents","volume":"27","year":"2016","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113842_bib60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jop.2016.0188","article-title":"The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies","volume":"34","author":"Cavet ME","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib61","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): an emerging target for the treatment of glaucoma","volume":"55","author":"Cavet ME","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib62","first-page":"275","article-title":"Nitric oxide donating anti-glaucoma drugs: advances and prospects","volume":"18","author":"Mao","year":"2020","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2021.113842_bib63","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/bjo.2003.028357","article-title":"Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma","volume":"88","author":"Galassi","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/jop.2009.0120","article-title":"A\u00a0novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma","volume":"26","author":"Borghi","year":"2010","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.exer.2011.03.001","article-title":"Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models","volume":"93","author":"Krauss","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jop.2016.0188","article-title":"The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies","volume":"34","author":"Cavet ME","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","article-title":"Effects of prostaglandin analogues on aqueous humor outflow pathways","volume":"30","author":"Winkler NS","year":"2014","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.ejmech.2021.113842_bib69","first-page":"S279","article-title":"Current therapeutic options and treatments in development for the management of primary open-angle glaucoma","volume":"23","author":"Liebmann Jm","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113842_bib70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","article-title":"Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension critical evaluation of latanoprostene bunod in the treatment of glaucoma","volume":"18","author":"Kaufman Pl","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113842_bib71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40265-018-0914-6","article-title":"Latanoprostene Bunod Ophthalmic Solution 0.024%: a review in open-angle glaucoma and ocular hypertension","volume":"78","author":"Sm","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113842_bib72","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.exer.2011.03.001","article-title":"Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models","volume":"93","author":"Krauss Ah","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib73","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s12325-016-0385-7","article-title":"Efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study","volume":"33","author":"Kawase K","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib74","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s12325-016-0385-7","article-title":"Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER Study","volume":"33","author":"Kawase K","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib75","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2021.113842_bib76","article-title":"Hypotensive and neuroprotective effects of K-115, a novel rho-kinase inhibitor","volume":"48","author":"Mizuno","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib77","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1055\/s-0032-1316771","article-title":"A\u00a0practical synthesis of (S)-tert-Butyl 3-Methyl-1,4-diazepane-1-carboxylate, the key intermediate of rho\u2013kinase inhibitor K-115","volume":"44","author":"Shibuya","year":"2012","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2021.113842_bib78","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3987\/COM-11-12230","article-title":"A\u00a0practical synthesis of novel rho-kinase inhibitor, (S)-4-fluoro-5-(2-methyl-1,4-diazepan-1-ylsulfonyl)- isoquinoline","volume":"83","author":"Noriaki Gomi","year":"2011","journal-title":"Heterocycles"},{"key":"10.1016\/j.ejmech.2021.113842_bib79","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1080\/14656566.2017.1378344","article-title":"Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma","volume":"18","author":"Inoue","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113842_bib80","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1038\/s41598-019-40194-5","article-title":"Effect of ripasudil on diabetic macular edema","volume":"9","author":"Minami Y","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113842_bib81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00417-018-4191-6","article-title":"Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats","volume":"257","author":"Wada Y","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10792-019-01198-2","article-title":"Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor","volume":"40","author":"Matsumura R","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib83","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/jop.2020.0082","article-title":"Akitoshi yoshida effect of rho kinase inhibitor ripasudil (K-115) on isolated porcine retinal arterioles","volume":"37","author":"Takayuki Kamiya","year":"2021","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/00498254.2015.1096981","article-title":"Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase","volume":"46","author":"Isobe","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2021.113842_bib85","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2147\/OPTH.S216907","article-title":"Ripasudil hydrochloride hydrate in the T reatment of glaucoma: safety, efficacy, and patient selection","volume":"14","author":"Nakamura","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1358\/dot.2020.56.9.3178110","article-title":"An update on ripasudil for the treatment of glaucoma and ocular hypertension","volume":"56","author":"Testa","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2021.113842_bib87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004872-200501000-00017","article-title":"Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats","volume":"23","author":"Mita S","year":"2005","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.ejmech.2021.113842_bib88","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1167\/iovs.13-13842","article-title":"The novel rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma","volume":"55","author":"Yamamoto","year":"2014","journal-title":"Invest. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2021.113842_bib89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","article-title":"Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension:3-month interim analysis of ROCK-J, a post-marketing surveillance study","volume":"36","author":"TaniharaH","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10792-020-01615-x","article-title":"Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma","volume":"41","author":"Ono","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib91","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","article-title":"Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study","volume":"10","author":"Futakuchi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113842_bib92","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","article-title":"Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study","volume":"36","author":"Tanihara","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib93","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1016\/j.bmcl.2013.09.040","article-title":"3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors","volume":"23","author":"Boland","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113842_bib94","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib95","series-title":"RHOPRESSA (Netarsudil Ophthalmic solution)0.02%, for Topical Ophthalmic Use: US Prescribing Information","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113842_bib96","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","article-title":"Netarsudil ophthalmic solution 0.02%: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113842_bib97","article-title":"Status of Rho kinase inhibitors in glaucoma therapeutics-an overview","author":"Saha","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib98","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2021.113842_bib99","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","article-title":"Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma","volume":"26","author":"Sturdivant","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113842_bib100","first-page":"155","article-title":"Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics","volume":"30","author":"Sinzinger","year":"1997","journal-title":"Lymphology"},{"key":"10.1016\/j.ejmech.2021.113842_bib101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000068942","article-title":"Isoprostane 8-epi-prostaglandin F2 alpha decreases lymph capillary pressure in patients with primary lymphedema","volume":"40","author":"Amann-Vesti","year":"2003","journal-title":"J.\u00a0Vasc. Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib102","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2013.6867","article-title":"A\u00a0new target for glaucoma therapy","volume":"131","author":"Zarbin","year":"2013","journal-title":"Jama Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","article-title":"Br Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension","volume":"100","author":"Lewis RA","year":"2016","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ejmech.2021.113842_bib104","series-title":"Manufacturer's Information: RHO-PRESSA (Netarsudil Ophthalmic Solution) 0.02% Product Monograph","author":"Inc","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113842_bib105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial","volume":"207","author":"Asrani S","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2021.113842_bib106","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.113842_bib107","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.3390\/molecules25194422","article-title":"AR12286 alleviates TGF-beta-related myofibroblast transdifferentiation and reduces fibrosis after glaucoma filtration surgery","volume":"25","author":"Cheng","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113842_bib108","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1248\/bpb.b19-00567","article-title":"Development of a novel intraocular-pressure-lowering therapy targeting ATX","volume":"42","author":"Nagano","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.113842_bib109","series-title":"8-Substituted\u2009imidazopyrimidinone Derivative Having Autotaxin Inhibitory Activity","author":"Nagano T","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113842_bib110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nsmb.1998","article-title":"Crystal structure of autotaxin and insight into GPCR activation by lipid mediators","volume":"18","author":"Nishimasu H","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113842_bib111","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nsmb.1980","article-title":"Structural basis of substrate discrimination and integrin binding by autotaxin","volume":"18","author":"Hausmann J","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113842_bib112","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/14728222.2021.1969362","article-title":"Tackling retinal ganglion cell apoptosis in glaucoma: role of adenosine receptors","volume":"25","author":"Agarwal","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2021.113842_bib113","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0022-3565(25)09553-9","article-title":"Adenosine receptor activation modulates intraocular pressure in rabbits","volume":"273","author":"CE","year":"1995","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113842_bib114","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1006\/exer.1997.0296","article-title":"Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomol-gus monkeys","volume":"64","author":"Tian B","year":"1997","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2021.113842_bib115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjp.0704267","article-title":"A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse","volume":"134","author":"Avila My","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113842_bib116","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.bbagen.2013.01.005","article-title":"Adenosine, adenosine receptors and glaucoma: an updated overview","volume":"1830","author":"Yisheng Zhong","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.113842_bib117","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/jop.2015.0148","article-title":"A\u00a0dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 Weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma","volume":"32","author":"Myers","year":"2016","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:31:57Z","timestamp":1759329117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421006917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":117,"alternative-id":["S0223523421006917"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113842","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113842"}}